Overview
The Registry was set up to:
- estimate the extent (incidence/prevalence) of growth hormone therapy in the Italian population
- evaluate the appropriateness of the growth hormone prescription
The RNAOC collection system has been computerized since 2011 and is based on a web platform that allows the online reporting of the prescription of growth hormone therapy by the accredited centers of 15 regions and 2 autonomous provinces and on the connection with the other local databases, activated according to regional provisions.
The Italian Medicines Agency (AIFA) has defined since 2004 with Note 39 the conditions in which this therapy is reimbursable by the NHS and has confirmed the assignment to the National Institute of Health of the national pharmacosurveillance of this therapy through the National Register of the Growth Hormone Assumers.
The RNAOC is included in the Decree of the President of the Council of Ministers of 3 March 2017 (GU n.109 of 12/5/2017) which identifies the surveillance systems and the national and regional registers to implement epidemiological surveillance on diseases and treatments of relevance for public health
Public funding
Demographics
Dataset
Contact
Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, Istituto Superiore di Sanità-ISS, Via Giano della Bella 34, 00161, Rome, Italy